Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 2, 2015

Primary Completion Date

October 19, 2016

Study Completion Date

October 19, 2016

Conditions
Progressive Supranuclear Palsy
Interventions
DRUG

BIIB092

See Arm Descriptions for dosing information.

DRUG

Placebo

See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)

Trial Locations (13)

Unknown

The University of Alabama at Birmingham, Birmingham

David Geffen School of Medicine at UCLA, Los Angeles

University of California San Diego, San Diego

University of California, San Francisco, Medical Center at Parnassus, San Francisco

Parkinsons Disease and Movement Disorders Center of Boca Raton, Boca Raton

University of Florida College of Medicine, Gainesville

University of South Florida, Tampa

The University of Chicago Department of Neurology, Chicago

University of Minnesota Medical School, Minneapolis

Robert Wood Johnson Medical School, New Brunswick

Columbia University Medical Center, New York

Hospital of the University of Pennsylvania, Philadelphia

The University of Texas Southwestern Medical Center, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY